Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18045583 | 0.90 | TSHR (0.60) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL3292782 | 0.88 | TSHR (0.75) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL18045549 | 0.88 | TSHR (0.58) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL250472 | 0.86 | TSHR (0.67) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL300767 | 0.86 | LOXL2 (0.64) | TSHRLOXL2KCNJ1KCNH2IDO1 | |
| SCHEMBL18913824 | 0.84 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL30758863 | 0.84 | TSHR (0.69) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL173192 | 0.84 | LOXL2 (0.61) | TSHRLOXL2KCNJ1KCNH2IDO1 | |
| SCHEMBL7317557 | 0.83 | TSHR (0.62) | TSHRLOXL2KCNJ1KCNH2HRH3 | |
| SCHEMBL8094543 | 0.82 | POLB (0.68) | TSHRLOXL2KCNJ1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0239354-A2 | 2,2-Dinitrophenylethane derivatives and their application as protecting compounds | Wendstone Chemicals P.L.C. (GB) | 1987-09-30 | — | — | EP | claimed |
| CN-110950781-A | Novel diamine, polyamic acid, and polyimide | 日产化学工业株式会社 | 2020-04-03 | — | — | CN | disclosed |
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | NISSAN CHEMICAL INDUSTRIES. LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| CN-105683155-A | Novel diamine, polyamic acid, and polyimide | 日产化学工业株式会社 | 2016-06-15 | — | — | CN | disclosed |
| EP-2771005-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-6177444-B1 | ANTIISCHEMIC AGENTS; ANTIARRHYTHMIA AGENTS | MEDCO CORP. | 2001-01-23 | — | — | US | disclosed |
| US-6147250-A | TREATING DISEASES MEDIATED BY VASCULAR CELL ADHESION MOLECULE-1, INCLUDING CARDIOVASCULAR AND INFLAMMATORY DISEASES; SUCCINOBUCOL | ATHEROGENICS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6140496-A | Precursors for deoxyribonucleotides containing non-standard nucleosides | BENNER, STEVEN | 2000-10-31 | — | — | US | disclosed |
| EP-1025106-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | Medco Research, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-5939432-A | Thiophenes useful for modulating the adenosine receptor | MEDCO RESEARCH, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999021617-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | MEDCO RESEARCH, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-5164515-A | Chemical compounds | WENDSTONE CHEMICALS PLC (GB) | 1992-11-17 | — | — | US | disclosed |
| EP-0239354-A2 | 2,2-Dinitrophenylethane derivatives and their application as protecting compounds | Wendstone Chemicals P.L.C. (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | H1-2, H1-4, H1-0 | TSHR 2393/4885LOXL2 1404/4885KCNJ1 4460/4885 |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | H1-4, H1-2, H1-5 | TSHR 3020/4885LOXL2 1149/4885KCNJ1 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.